Table 1.
RTK fusions: Fusion partners and additional details for each of the 12 RTK fusion cases identified in our cohort
| Fusion oncogene | Fusion partner | Known fusion partner | Validation method | Validation result | Mismatch Repair Status | Method of detection MSS/MSI status | MLH1 promoter hypermethylation (Y/N) | Site of primary tumor | Stage at diagnosis | Histology |
|---|---|---|---|---|---|---|---|---|---|---|
| RET | NCOA4 | Yes | - | - | Deficient | IHC and PCR | Yes | Ascending | I | Signet-ring-cell |
| RET | NCOA4 | Yes | - | - | Deficient | IHC and PCR | Yes | Descending | II | NA |
| NTRK1 | TPR | Yes | IHC and Archer Dx | Confirm | Deficient | IHC | Yes | Ascending | IV | Mucinous features |
| NTRK1 | LMNA | Yes | IHC | Confirm | Deficient | IHC | Yes | Ascending | II | Mucinous |
| NTRK1 | LMNA | Yes | IHC and Archer Dx | Confirm | Deficient | IHC | Yes | Ascending | II | Medullary |
| NTRK1 | LMNA | Yes | IHC | Confirm | Deficient | IHC and PCR | Yes | Cecum | III | Medullary features |
| ALK | CAD | Yes | FISH | Confirm | Proficient | IHC and PCR | NA | Cecum | IV | Poorly differentiated |
| ALK | EML4 | Yes | - | - | Deficient | IHC | Yes | Ascending | IV | Medullary and signet-ring-cell features |
| BRAF | ARMC10 | Yes | - | - | Deficient | IHC | Yes | Ascending | III | Poorly differentiated |
| FGFR2 | TACC2 | Yes | Archer Dx | Confirm | Proficient | IHC and PCR | NA | Rectosigmoid | IV | NA |
| ROS1 | GOPC | Yes | - | - | Proficient | IHC and PCR | NA | Rectosigmoid | IV | Mucinous features |
| NRG1 | KIF13B | Yes | Archer Dx | Confirm | Proficient | IHC | NA | Unknown | IV | NA |
FISH: Fluorescence in situ hybridization. IHC: Immunohistochemistry. - : Tissue not available for further testing.